
Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics
Frontiers of Medicine ›› 2024, Vol. 18 ›› Issue (5) : 911-920.
Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics
Cancer is a major public health problem and represents substantial disparities worldwide. This study reported estimates for 36 cancers across 185 countries by incidence, mortality, 5-year prevalence, mortality-to-prevalence ratio (MPR), and mortality-to-incidence ratio (MIR) to examine its association with human development index (HDI) and gross national income (GNI). Data were collected from the GLOBOCAN 2020. MPR and MIR were calculated by sex, age group, country, and cancer type and then summarized into totals. Segi’s population and global cancer spectrum were used to calculate age- and type-standardized ratios. Correlation analyses were conducted to assess associations. Results showed that breast cancer was the most diagnosed cancer globally. Low- and middle-income countries had high MPR and MIR. Cancers of esophagus, pancreas, and liver had the highest ratios. Males and the older population had the highest ratios. HDI and GNI were positively correlated with incidence and mortality but negatively correlated with MPR/MIR. Substantial disparities in cancer burden were observed among 36 cancer types across 185 countries. Socioeconomic development may contribute to narrowing these disparities, and tailored strategies are crucial for regional- and country-specific cancer control.
cancer / burden / mortality-to-prevalence ratio / mortality-to-incidence ratio / disparities / global
Tab.1 Global cancer burden by sex, human development index, and region and country, 2020 |
Incidence (No.) | Mortality (No.) | Prevalence (No.) | Mortality-to-prevalence ratio | Mortality-to-incidence ratio | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Crude | Age-standardized | Age- and type-standardized | Crude | Age-standardized | Age- and type-standardized | ||||||
Worldwide | 19 292 789 | 9 958 133 | 50 550 287 | 0.20 | 0.15 | 0.26 | 0.52 | 0.39 | 0.41 | ||
Sex | |||||||||||
Male | 10 065 305 | 5 528 810 | 24 828 480 | 0.22 | 0.17 | 0.34 | 0.55 | 0.44 | 0.51 | ||
Female | 9 227 484 | 4 429 323 | 25 721 807 | 0.17 | 0.13 | 0.24 | 0.48 | 0.35 | 0.43 | ||
Human development index (HDI)a | |||||||||||
Very high | 8 390 110 | 3 183 923 | 27 181 209 | 0.12 | 0.05 | 0.12 | 0.38 | 0.18 | 0.26 | ||
High | 7 026 620 | 4 317 256 | 15 411 087 | 0.28 | 0.15 | 0.28 | 0.61 | 0.39 | 0.43 | ||
Medium | 2 959 754 | 1 864 270 | 6 249 879 | 0.30 | 0.21 | 0.31 | 0.63 | 0.50 | 0.46 | ||
Low | 698 436 | 469 500 | 1 219 219 | 0.39 | 0.32 | 0.36 | 0.67 | 0.59 | 0.53 | ||
Region and countryb | |||||||||||
Asia | 9 391 695 | 5 750 836 | 20 301 710 | 0.28 | 0.18 | 0.28 | 0.61 | 0.43 | 0.43 | ||
China | 4 568 754 | 3 002 899 | 9 294 006 | 0.32 | 0.16 | 0.25 | 0.66 | 0.40 | 0.42 | ||
India | 1 324 413 | 851 678 | 2 720 251 | 0.31 | 0.23 | 0.32 | 0.64 | 0.53 | 0.49 | ||
Indonesia | 396 914 | 234 511 | 946 088 | 0.25 | 0.17 | 0.22 | 0.59 | 0.43 | 0.37 | ||
Japan | 1 028 658 | 420 124 | 2 710 728 | 0.15 | 0.05 | 0.07 | 0.41 | 0.16 | 0.21 | ||
The Republic of Korea | 230 317 | 88 597 | 630 991 | 0.14 | 0.05 | 0.08 | 0.38 | 0.15 | 0.23 | ||
Mongolia | 5714 | 4469 | 9012 | 0.50 | 0.27 | 0.18 | 0.78 | 0.58 | 0.34 | ||
Thailand | 190 636 | 124 866 | 426 366 | 0.29 | 0.16 | 0.21 | 0.65 | 0.40 | 0.41 | ||
Turkey | 233 834 | 126 335 | 581 636 | 0.22 | 0.11 | 0.21 | 0.54 | 0.31 | 0.43 | ||
Europe | 4 399 659 | 1 955 889 | 13 510 129 | 0.14 | 0.06 | 0.15 | 0.44 | 0.21 | 0.29 | ||
France | 467 965 | 185 621 | 1 501 881 | 0.12 | 0.05 | 0.11 | 0.40 | 0.17 | 0.29 | ||
Germany | 628 519 | 252 065 | 2 188 176 | 0.12 | 0.04 | 0.11 | 0.40 | 0.15 | 0.26 | ||
Italy | 415 269 | 174 759 | 1 230 693 | 0.14 | 0.05 | 0.12 | 0.42 | 0.16 | 0.29 | ||
Russian Federation | 591 371 | 312 122 | 1 580 383 | 0.20 | 0.10 | 0.22 | 0.53 | 0.29 | 0.37 | ||
United Kingdom | 457 960 | 179 648 | 1 514 320 | 0.12 | 0.04 | 0.10 | 0.39 | 0.15 | 0.25 | ||
Africa | 1 105 336 | 709 404 | 2 158 533 | 0.33 | 0.27 | 0.34 | 0.64 | 0.55 | 0.52 | ||
Egypt | 134 632 | 89 042 | 278 165 | 0.32 | 0.20 | 0.28 | 0.66 | 0.46 | 0.45 | ||
Ethiopia | 77 352 | 51 865 | 130 858 | 0.40 | 0.34 | 0.31 | 0.67 | 0.58 | 0.46 | ||
Nigeria | 124 815 | 78 899 | 233 911 | 0.34 | 0.27 | 0.30 | 0.63 | 0.54 | 0.46 | ||
Somalia | 10 134 | 7439 | 13 212 | 0.56 | 0.48 | 0.39 | 0.73 | 0.64 | 0.53 | ||
South Africa | 108 168 | 56 802 | 262 455 | 0.22 | 0.16 | 0.26 | 0.53 | 0.42 | 0.45 | ||
Latin America and the Caribbean | 1 449 034 | 704 039 | 3 781 938 | 0.19 | 0.13 | 0.27 | 0.49 | 0.35 | 0.46 | ||
Argentina | 130 878 | 70 074 | 358 627 | 0.20 | 0.11 | 0.26 | 0.54 | 0.33 | 0.43 | ||
Brazil | 592 212 | 259 949 | 1 563 761 | 0.17 | 0.11 | 0.24 | 0.44 | 0.32 | 0.44 | ||
Colombia | 113 221 | 54 987 | 293 524 | 0.19 | 0.13 | 0.30 | 0.49 | 0.36 | 0.44 | ||
Mexico | 195 499 | 90 222 | 530 602 | 0.17 | 0.11 | 0.30 | 0.46 | 0.33 | 0.45 | ||
Peru | 69 849 | 34 976 | 175 090 | 0.20 | 0.15 | 0.30 | 0.50 | 0.41 | 0.45 | ||
Northern America | 2 569 519 | 704 931 | 9 497 874 | 0.07 | 0.04 | 0.12 | 0.27 | 0.15 | 0.25 | ||
Canada | 274 364 | 86 684 | 1 023 261 | 0.08 | 0.04 | 0.13 | 0.32 | 0.15 | 0.32 | ||
The United States of America | 2 281 658 | 612 390 | 8 432 938 | 0.07 | 0.04 | 0.12 | 0.27 | 0.15 | 0.25 | ||
Oceania | 250 812 | 67 520 | 979 868 | 0.07 | 0.05 | 0.12 | 0.27 | 0.17 | 0.27 | ||
Australia | 200 021 | 48 236 | 808 997 | 0.06 | 0.03 | 0.11 | 0.24 | 0.10 | 0.26 | ||
New Zealand | 35 934 | 10 508 | 142 413 | 0.07 | 0.04 | 0.11 | 0.29 | 0.15 | 0.28 |
aExcluding Democratic People’s Republic of Korea and Somalia because the United Nations Development Program (UNDP) did not report HDI 2020 in these countries. bCountries were selected in major endemic regions by incidence. |
Tab.2 Global cancer burden by cancer type, 2020 |
Cancer type | Incidence (No.) | Mortality (No.) | Prevalence (No.) | Mortality-to-prevalence ratio | Mortality-to-incidence ratio | ||||
---|---|---|---|---|---|---|---|---|---|
Crude | Age-standardized | Crude | Age-standardized | ||||||
All cancers | 19 292 789 | 9 958 133 | 50 550 287 | 0.20 | 0.15 | 0.52 | 0.39 | ||
All cancers excl. nonmelanoma skin cancer | 18 094 716 | 9 894 402 | 44 091 402 | 0.22 | 0.15 | 0.55 | 0.39 | ||
Oesophagus | 604 100 | 544 076 | 666 388 | 0.82 | 0.72 | 0.90 | 0.70 | ||
Pancreas | 495 773 | 466 003 | 379 958 | 1.23 | 0.56 | 0.94 | 0.62 | ||
Gallbladder | 115 949 | 84 695 | 137 466 | 0.62 | 0.55 | 0.73 | 0.61 | ||
Mesothelioma | 30 870 | 26 278 | 37 047 | 0.71 | 0.50 | 0.85 | 0.46 | ||
Stomach | 1 089 103 | 768 793 | 1 805 968 | 0.43 | 0.47 | 0.71 | 0.60 | ||
Liver | 905 677 | 830 180 | 994 539 | 0.83 | 0.44 | 0.92 | 0.73 | ||
Lung | 2 206 771 | 1 796 144 | 2 604 791 | 0.69 | 0.36 | 0.81 | 0.62 | ||
Hypopharynx | 84 254 | 38 599 | 132 717 | 0.29 | 0.33 | 0.46 | 0.44 | ||
Brain, central nervous system | 308 102 | 251 329 | 837 152 | 0.30 | 0.23 | 0.82 | 0.64 | ||
Multiple myeloma | 176 404 | 117 077 | 450 579 | 0.26 | 0.23 | 0.66 | 0.52 | ||
Kaposi sarcoma | 34 270 | 15 086 | 82 033 | 0.18 | 0.21 | 0.44 | 0.48 | ||
Prostate | 1 414 259 | 375 304 | 4 956 901 | 0.08 | 0.21 | 0.27 | 0.30 | ||
Larynx | 184 615 | 99 840 | 518 380 | 0.19 | 0.20 | 0.54 | 0.45 | ||
Leukemia | 474 519 | 311 594 | 1 340 506 | 0.23 | 0.20 | 0.66 | 0.56 | ||
Bladder | 573 278 | 212 536 | 1 720 625 | 0.12 | 0.19 | 0.37 | 0.27 | ||
Lip, oral cavity | 377 713 | 177 757 | 959 248 | 0.19 | 0.19 | 0.47 | 0.45 | ||
Nasopharynx | 133 354 | 80 008 | 382 507 | 0.21 | 0.19 | 0.60 | 0.44 | ||
Cervix uteri | 604 127 | 341 831 | 1 495 211 | 0.23 | 0.19 | 0.57 | 0.40 | ||
Colorectum | 1 931 590 | 935 173 | 5 253 335 | 0.18 | 0.17 | 0.48 | 0.37 | ||
Oropharynx | 98 412 | 48 143 | 258 543 | 0.19 | 0.17 | 0.49 | 0.32 | ||
Vagina | 17 908 | 7995 | 44 613 | 0.18 | 0.17 | 0.45 | 0.35 | ||
Non-Hodgkin lymphoma | 544 352 | 259 793 | 1 544 488 | 0.17 | 0.16 | 0.48 | 0.40 | ||
Ovary | 313 959 | 207 252 | 823 315 | 0.25 | 0.15 | 0.66 | 0.37 | ||
Breast | 2 261 419 | 684 996 | 7 790 717 | 0.09 | 0.14 | 0.30 | 0.30 | ||
Hodgkin lymphoma | 83 087 | 23 376 | 281 112 | 0.08 | 0.13 | 0.28 | 0.25 | ||
Salivary glands | 53 583 | 22 778 | 160 292 | 0.14 | 0.13 | 0.43 | 0.28 | ||
Kidney | 431 288 | 179 368 | 1 207 547 | 0.15 | 0.12 | 0.42 | 0.34 | ||
Vulva | 45 240 | 17 427 | 135 892 | 0.13 | 0.12 | 0.39 | 0.30 | ||
Nonmelanoma skin cancer | 1 198 073 | 63 731 | 6 458 885 | 0.01 | 0.09 | 0.05 | 0.18 | ||
Penis | 36 068 | 13 211 | 102 157 | 0.13 | 0.08 | 0.37 | 0.22 | ||
Corpus uteri | 417 367 | 97 370 | 1 415 213 | 0.07 | 0.06 | 0.23 | 0.16 | ||
Testis | 74 458 | 9334 | 296 686 | 0.03 | 0.05 | 0.13 | 0.16 | ||
Melanoma of skin | 324 635 | 57 043 | 1 092 818 | 0.05 | 0.04 | 0.18 | 0.13 | ||
Thyroid | 586 202 | 43 646 | 1 984 927 | 0.02 | 0.03 | 0.07 | 0.08 |
Note: Specific cancer type is ranked based on the age-standardized mortality-to-prevalence ratio. Excl., excluding. |
[1] |
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209–249
CrossRef
ADS
Google scholar
|
[2] |
Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol 2021; 18(10): 663–672
CrossRef
ADS
Google scholar
|
[3] |
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021; 127(16): 3029–3030
CrossRef
ADS
Google scholar
|
[4] |
Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ 1994; 72(3): 429–445
|
[5] |
Chen XC, Chen XZ. Epidemiological differences in haematological malignancies between Europe and China. Lancet Oncol 2014; 15(11): e471–e472
CrossRef
ADS
Google scholar
|
[6] |
Mubarik S, Yu Y, Wang F, Malik SS, Liu X, Fawad M, Shi F, Yu C. Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: an age-period-cohort analysis. J Adv Res 2022; 37: 185–196
CrossRef
ADS
Google scholar
|
[7] |
Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O, Verbeek AL, Kiemeney LA. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health 2011; 21(5): 573–577
CrossRef
ADS
Google scholar
|
[8] |
Wang B, He F, Hu Y, Wang Q, Wang D, Sha Y, Wu J. Cancer incidence and mortality and risk factors in member countries of the “Belt and Road” initiative. BMC Cancer 2022; 22(1): 582
CrossRef
ADS
Google scholar
|
[9] |
Choi E, Lee S, Nhung BC, Suh M, Park B, Jun JK, Choi KS. Cancer mortality-to-incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. Epidemiol Health 2017; 39: e2017006
CrossRef
ADS
Google scholar
|
[10] |
Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 2012; 13(8): 790–801
CrossRef
ADS
Google scholar
|
[11] |
Savoldi A, Carrara E, Gladstone BP, Azzini AM, Göpel S, Tacconelli E. Gross national income and antibiotic resistance in invasive isolates: analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list. J Antimicrob Chemother 2019; 74(12): 3619–3625
CrossRef
ADS
Google scholar
|
[12] |
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015; 24(10): 1495–1506
CrossRef
ADS
Google scholar
|
[13] |
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021; 134(7): 783–791
CrossRef
ADS
Google scholar
|
[14] |
Sharma R. Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990–2016: evidence from Global Burden of Disease Study 2016. Breast Cancer 2019; 26(4): 428–445
CrossRef
ADS
Google scholar
|
[15] |
Xie L, Shang ZJ. Oral cancer incidence, mortality, and mortality-to-incidence ratio are associated with human development index in China, 1990–2019. BioMed Res Int 2022; 2022: 6457840
CrossRef
ADS
Google scholar
|
[16] |
Sobhani S, Masinaei M, Fattahi N, Moghaddam SS, Naderimagham S, Rezaei N, Fateh SM, Madadi Z, Ahmadi N, Roshani S, Khalilabad MR, Kompani F, Farzadfar F. National and provincial population-based incidence and mortality of skin cancer in Iran; 1990–2016. Asia Pac J Clin Oncol 2021; 17(5): e162–e169
CrossRef
ADS
Google scholar
|
[17] |
Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010; 376(9747): 1186–1193
CrossRef
ADS
Google scholar
|
[18] |
Sylla BS, Wild CP. A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent. Int J Cancer 2012; 130(2): 245–250
CrossRef
ADS
Google scholar
|
[19] |
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival: analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers during 2000–2014 from 322 population-based registries in 71 countries (CONCORD-3). Lancet 2018; 391(10125): 1023–1075
CrossRef
ADS
Google scholar
|
[20] |
Pervaiz R, Faisal F. Cancer incidence and mortality are associated with human development index and health setups in Africa. J Egypt Natl Canc Inst 2017; 29(3): 123–126
CrossRef
ADS
Google scholar
|
[21] |
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371(11): 1039–1049
CrossRef
ADS
Google scholar
|
[22] |
US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for pancreatic cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2019; 322(5): 438–444
CrossRef
ADS
Google scholar
|
[23] |
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020; 159(1): 335–349. e15
CrossRef
ADS
Google scholar
|
[24] |
Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol 2020; 8(6): 468–470
CrossRef
ADS
Google scholar
|
[25] |
Zhu Y, Shao X, Wang X, Liu L, Liang H. Sex disparities in cancer. Cancer Lett 2019; 466: 35–38
CrossRef
ADS
Google scholar
|
[26] |
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143(S2 Suppl2): 22–36
CrossRef
ADS
Google scholar
|
[27] |
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11(3): 249–257
CrossRef
ADS
Google scholar
|
[28] |
Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 2017; 27(1): 3–10
CrossRef
ADS
Google scholar
|
[29] |
Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol 2017; 18(12): 1579–1589
CrossRef
ADS
Google scholar
|
[30] |
Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019. J Hematol Oncol 2021; 14(1): 197
CrossRef
ADS
Google scholar
|
[31] |
Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer 2016; 139(11): 2436–2446
CrossRef
ADS
Google scholar
|
[32] |
Veisani Y, Jenabi E, Khazaei S, Nematollahi S. Global incidence and mortality rates in pancreatic cancer and the association with the human development index: decomposition approach. Public Health 2018; 156: 87–91
CrossRef
ADS
Google scholar
|
[33] |
Rafiemanesh H, Mehtarpour M, Khani F, Hesami SM, Shamlou R, Towhidi F, Salehiniya H, Makhsosi BR, Moini A. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis 2016; 8(6): 1094–1102
CrossRef
ADS
Google scholar
|
[34] |
Shao SY, Hu QD, Wang M, Zhao XY, Wu WT, Huang JM, Liang TB. Impact of national human development index on liver cancer outcomes: transition from 2008 to 2018. World J Gastroenterol 2019; 25(32): 4749–4763
CrossRef
ADS
Google scholar
|
[35] |
Sharma R. An examination of colorectal cancer burden by socioeconomic status: evidence from GLOBOCAN 2018. EPMA J 2020; 11(1): 95–117
CrossRef
ADS
Google scholar
|
[36] |
GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258): 1250–1284
CrossRef
ADS
Google scholar
|
[37] |
Ocran Mattila P, Ahmad R, Hasan SS, Babar ZU. Availability, affordability, access, and pricing of anti-cancer medicines in low- and middle-income countries: a systematic review of literature. Front Public Health 2021; 9: 628744
CrossRef
ADS
Google scholar
|
[38] |
Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol 2021; 22(10): 1367–1377
CrossRef
ADS
Google scholar
|
[39] |
World Health Organization. WHO’s Framework Convention on Tobacco Control (FCTC). Available at the website of World Health Organization
|
补充材料
FMD-23077-OF-CWQ_suppl_1 (93 KB)
/
〈 |
|
〉 |